CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model
Dr. Yanan Wang (Leiden, The Netherlands)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs Yanan Wang showed in a humanised animal model, the CETP-inhibitor anacetrapib reduced atherosclerosis development, by lowering non-HDL-c levels, via increased uptake in the liver. In addition, anacetrapib reduces plasma PCSK9 levels.